Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the ...

Teva Pharmaceuticals has launched the first generic GLP-1 drug for weight loss in adults and adolescents; a lower-cost ...

A Blue Cross Blue Shield study of one decade worth of claims for Saxenda and Wegovy found 58% of patients quit the weight-loss drugs after 12 weeks.

Parsippany: Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., has announced the FDA approval and U.S. launch of a generic version of Saxenda ...

Medicare drug plans don’t cover Saxenda because Medicare doesn’t cover GLP-1 agonists when prescribed for weight loss.

Saxenda falls outside Medicare drug plan coverage because Medicare does not cover GLP-1 agonists when doctors prescribe them specifically for weight management.

A report by Blue Shield notes that more than half of people on weight loss medications such as Wegovy and Saxenda stop taking the drugs before they can reap the benefits ...

The weight-loss drug liraglutide (Saxenda) helped obese children lower their BMI and reach a healthier weight, researchers report.

Novo Nordisk weight-loss drug is effective for kids as young as 6, study shows Side effects were common among those given the drug, particularly gastrointestinal effects such as nausea, vomiting ...

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with diet and exercise, a small new study shows. Liraglutide lowered body ...

More than 1.1 million prescriptions for the weight-loss drugs Saxenda and Wegovy have been issued in South Korea over the ...